Physician profile
Jeffrey Allen Hatcher
NPI 1437128220
$423.20
in general payments reported to CMS, 2019-2025
10 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.76 · 2021: $40.49 · 2022: $78.32 · 2023: $80.27 · 2024: $20.77 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $87.70 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $82.01 | 2022-2025 | |
| Astellas Pharma US INC | $61.92 | 2023-2025 | Veozah |
| Abbvie INC. | $61.30 | 2019-2021 | |
| Hologic Sales and Service, LLC | $33.79 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $31.30 | 2023-2025 | Exparel |
| Amag Pharmaceuticals, INC. | $20.24 | 2019 | |
| Daiichi Sankyo INC. | $16.38 | 2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $15.64 | 2023 | |
| Duchesnay USA Incorporated | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hatcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.